Literature DB >> 34213772

Report of AAPM Task Group 219 on independent calculation-based dose/MU verification for IMRT.

Timothy C Zhu1, Sotiris Stathakis2, Jennifer R Clark3, Wenzheng Feng4, Dietmar Georg5, Shannon M Holmes6, Stephen F Kry7, Chang-Ming Charlie Ma8, Moyed Miften9, Dimitris Mihailidis1, Jean M Moran10, Niko Papanikolaou2, Bjorn Poppe11, Ying Xiao1.   

Abstract

Independent verification of the dose per monitor unit (MU) to deliver the prescribed dose to a patient has been a mainstay of radiation oncology quality assurance (QA). We discuss the role of secondary dose/MU calculation programs as part of a comprehensive QA program. This report provides guidelines on calculation-based dose/MU verification for intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) provided by various modalities. We provide a review of various algorithms for "independent/second check" of monitor unit calculations for IMRT/VMAT. The report makes recommendations on the clinical implementation of secondary dose/MU calculation programs; on commissioning and acceptance of various commercially available secondary dose/MU calculation programs; on benchmark QA and periodic QA; and on clinically reasonable action levels for agreement of secondary dose/MU calculation programs.
© 2021 American Association of Physicists in Medicine.

Entities:  

Mesh:

Year:  2021        PMID: 34213772     DOI: 10.1002/mp.15069

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.506


  3 in total

1.  Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry.

Authors:  Yawo A C Fiagan; Evy Bossuyt; Melanie Machiels; Daan Nevens; Charlotte Billiet; Philip Poortmans; Thierry Gevaert; Dirk Verellen
Journal:  Phys Imaging Radiat Oncol       Date:  2022-05-13

2.  Integration of an Independent Monitor Unit Check for High-Magnetic-Field MR-Guided Radiation Therapy System.

Authors:  Jie Yang; Pengpeng Zhang; Neelam Tyagi; Paola Godoy Scripes; Ergys Subashi; Jiayi Liang; Dale Lovelock; James Mechalakos; Anyi Li; Seng B Lim
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 5.738

3.  Monte Carlo modeling of the Elekta Versa HD and patient dose calculation with EGSnrc/BEAMnrc.

Authors:  Holly M Parenica Paschal; Christopher N Kabat; Pavlos Papaconstadopoulos; Neil A Kirby; Pamela A Myers; Timothy D Wagner; Sotirios Stathakis
Journal:  J Appl Clin Med Phys       Date:  2022-08-19       Impact factor: 2.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.